Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (July 2024)
24 slides from Inmed Pharmaceuticals's investor presentation, July 2024
Slide 1: Corporate Presentation
Corporate Presentation July 2024 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights • Robust R&D pipeline with 3 candidates in dermatology, ocular and Alzheimer’s • A successful Phase 2 dermatology program, currently seeking partnerships • Library of proprietary analogs targeting diverse pharmaceutical applications • A revenue generating subsidiary
Slide 4: A Clinical Stage Pharmaceutical Company
A Clinical Stage Pharmaceutical Company A GLOBAL LEADER IN THE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF RARE CANNABINOIDS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of pharmaceutical programs • Screening of therapeutic • Chemical and • B2B supplier to
Slide 5: Drug Development Programs
Drug Development Programs
Slide 6: Pharmaceutical Pipeline
Pharmaceutical Pipeline HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 • In vivo studies – improved neuronal INM-901 CBx function, neuroprotection, other beneficial Alzheimer’s disease effects • Patent application filed INM-089 CBN • Planning for IND-enabling toxicology studies Dry Age-related Macu
Slide 7: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • Alzheimer’s accounts for 60-80% of the part of the brain that controls thought, memory dementia cases and la
Slide 8: INM-901: A Multi-factorial Approach
INM-901: A Multi-factorial Approach POTENTIALLY DISEASE-MODIFYING SMALL MOCECULE DRUG CANDIDATE A preferential signaling agonist for CB1/CB2 and Can safely pass the impacts PPAR signaling blood/brain barrier pathways Increased neurite Improved behavior and outgrowth in in vitro INM-901 cognitive fun
Slide 9: INM-901: Potential Multiple Mechanisms of Action
INM-901: Potential Multiple Mechanisms of Action INM-901 INM-901 Cytotoxicity • Proprietary small molecule compound Neuroinflammation can cross BBB Neuroprotection • May be formulated Neurite outgrowth orally • NOT expected to have Neuronal function intoxicating effects Locomotion • Preferential sig
Slide 10: Demonstrates Multiple Pharmacological Effects
Demonstrates Multiple Pharmacological Effects POTENTIAL TO TARGET SEVERAL BIOLOGICAL PATHWAYS ASSOCIATED WITH ALZHEIMER’S DISEASE Neuroprotection Neuritogenesis ALZ Behavioral Studies Studies Studies • Amyloid-β-induced model • Measured neurite length • Basal and locomotor activity compared to contr
Slide 11: INM-901 Summary Next steps
INM-901 Summary Next steps Research & Development • Small molecule, systemic delivery across the BBB • Long-term 6-month in 5xFAD with • Possibly deliverable via oral ingestion increasing sample size (on-going) • Planning study in PS19 Tau model • In vitro: Demonstrates 2 distinct features • On-goin
Slide 12: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans central vision. It happens when aging aged 40+ causes damage to the macula, the part • 12.6% of the U.S. population of the
Slide 13: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 14: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD A preferential signaling Ability to proactively protect ligand for CB1 and CB2 the retinal ganglion cells Demonstrated promise Improved the thickness in preserving retinal of the outer nuclear layer function in an INM-089 of the retina where the
Slide 15: INM-089 Summary Next steps
INM-089 Summary Next steps Research & Development • Proprietary small molecule drug candidate • Additional Protein and RNA analysis results are pending • Deliverable via IVT formulation • Continuing CMC activities for drug • In vitro: Demonstrates Neuroprotection of RGC substance and drug product vi
Slide 16: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 17: BayMedica Commercial Business
BayMedica Commercial Business
Slide 18: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C O S T- E F F E C T I V E N E S S High quality, bioidentical rare cannabinoids with exceptiona
Slide 19: BayMedica Financial Performance
BayMedica Financial Performance Calendar Year Revenue Growth US$ (Fiscal year ends June 30) (000’s) 2,500 • 278% growth: YoY F2023 v F2022 $2.3M • Trailing 12-month revenue is $5.6m 2,000 • Currently operating as a cash flow positive 1,500 $1.2M business $1.2M $1M 1,000 $895K • Quarterly fluctuation
Slide 20: Corporate
Corporate
Slide 21: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT, API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Neeta Jagpal, CPA Alexandra Mancini, MSc Jerry P. Griffin Shane Johnson, MD Chief Executive Officer Chief Financial Officer SVP, Clinical & Regulatory Aff
Slide 22: Financial Snapshot
Financial Snapshot As of 2024-06-28 Cash and Short-term Investments $7.6 M(1) Shares I/O 9.6 M(2) Options 0.6 M Warrants and Preferred Investment Options (9.6M @$0.83 cents) 10.2 M Fully Diluted Shares 20.4 M Close US$0.25 52-week High US$2.08 52-week Low US$0.21 Avg. Daily Volume (Trailing 50 Days)
Slide 23: Fiscal 2024 – Key Value Drivers
Fiscal 2024 – Key Value Drivers • Advance INM-901 in ALZ in long-term preclinical in vivo studies and manufacturing • Advance INM-089 in Dry AMD towards IND filing / human clinical trials • Evaluate INM-755 in itch for clinical and commercial partnerships • Target proprietary cannabinoid analogs for
Slide 24: Thank you!
Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications ir@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (July 2024) on 6ix